Table 1.
Patient characteristics at the registry baseline and exposure years in biological treatments.
| Biologics, Total | TNF Inhibitors | |||
|---|---|---|---|---|
| 6538 Patients | 2388 Patients | |||
| 13,841 Patient Years (py) | 5745 py | |||
| Mean (SD) | Median (Range) | Mean (SD) | Median (Range) | |
| Female sex, n (%) | 2534 (39.1) | 987 (41.3) | ||
| Age, years | 47.5 (14.1) | 48.0 (18.0–93.0) | 46.7 (13.8) | 47.0 (18.0–87.0) |
| Body mass index (BMI), kg/m2 | 29.1 (6.1) | 28.1 (14.2–61.1) | 29.0 (6.0) | 28.1 (15.8–57.9) |
| Duration of psoriasis, years | 19.5 (14.4) | 17.0 (0.0–74.0) | 18.6 (13.9) | 16.0 (0.0–68.0) |
| Nail psoriasis, n (%) | 3438 (52.8) ** | 1319 (55.2) | ||
| Psoriatic arthritis, n (%) | 2620 (40.3) ** | 1208 (50.6) | ||
| Multimorbid *, n (%) | 747 (11.4) ** | 251 (10.5) | ||
| Psoriasis area and severity index (PASI) | 16.1 (10.8) | 14.0 (0.0–72.0) | 15.3 (10.7) | 13.4 (0.0–70.8) |
| Body surface area (BSA) | 25.7 (21.0) | 20.0 (0.0–100.0) | 23.9 (20.6) | 17.0 (0.0–100.0) |
| Dermatology life quality index (DLQI) | 12.5 (7.5) | 12.0 (0.0–30.0) | 12.2 (7.5) | 12.0 (0.0 –30.0) |
| IL-17 Inhibitors | IL-12/23 and IL-23 Inhibitors | |||
| 2525 Patients | 2594 Patients | |||
| 3838 Exposure Years | 4357 Exposure Years | |||
| Mean (SD) | Median (Range) | Mean (SD) | Median (Range) | |
| Female sex, n (%) | 988 (39.1) | 1006 (38.8) | ||
| Age, years | 48.1 (14.0) | 49.0 (18.0–89.0) | 47.5 (14.4) | 48.0 (18.0–93.0) |
| BMI, kg/m2 | 29.2 (6.0) | 28.4 (16.6–61.1) | 29.4 (6.2) | 28.4 (14.2–60.9) |
| Duration of psoriasis, years | 20.0 (14.7) | 18.0 (0.0–74.0) | 19.7 (14.2) | 17.0 (0.0–70.0) |
| Nail psoriasis, n (%) | 1356 (53.7) | 1325 (51.1) | ||
| Psoriatic arthritis, n (%) | 1026 (40.6) | 906 (34.9) | ||
| Multimorbid *, n (%) | 312 (12.4) | 306 (11.8) | ||
| PASI | 16.6 (10.8) | 14.4 (0.0–70.8) | 16.3 (10.6) | 14.1 (0.0–72.0) |
| BSA | 26.9 (21.6) | 20.0 (0.0–100.0) | 26.0 (20.5) | 20.0 (0.0–98.0) |
| DLQI | 12.9 (7.5) | 12.0 (0.0–30.0) | 12.4 (7.5) | 12.0 (0.0–30.0) |
Significant differences (p < 0.05) between biologics and non-biologics (Table 2) are marked with **. Other treatment groups were not tested against each other. The number of patients is not additive because patients may have received more than one treatment. * Patients with 3 or more different comorbidity groups are referred to as multimorbid.